FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312297198> ?p ?o ?g. }

• W4312297198 endingPage "332" @default.
• W4312297198 startingPage "332" @default.
• W4312297198 abstract "Variances in the patients’ outcomes have been a well-documented challenge in anticoagulant therapy. A clinical encounter with a thromboembolic or a hemorrhagic event, due to subtherapeutic or adverse effects of an anticoagulant, is often managed by switching the anticoagulant agent into another, which is more specific and direct-acting. This management approach is usually associated with a financial burden. Additionally, the certainty of achieving better efficacy and safety profile is still questionable. Genetic variants affecting the protein sites that are involved in the anticoagulant pharmacokinetic and pharmacodynamics interactions have been suggested to contribute to the variability in the response to anticoagulant therapy. The current work reviewed the studies investigating the response variability associated with the anticoagulant therapy (heparins, rivaroxaban, apixaban, and dabigatran) and the potential pharmacogenes contributing to such response variability. Several genetic polymorphisms were reported as potential contributors to variances in response to anticoagulant therapy and were associated with adverse events. A link has been proposed for heparin resistance with single nucleotide polymorphisms (SNPs) of the anti-thrombin-encoding gene (SERPINC1) as well as heparin-induced thrombocytopenia with human leukocyte antigen (HLA) variant allele (HLA-DRB3*01:01). Several investigations also remarked variations in the serum drug level of direct oral anticoagulants (DOACs) that are associated with SNPs in the proteins contributing to the pharmacokinetics of the anticoagulant agent. Several studies discerned significant associations between SNPs in the ABCB1 gene and elevations in the serum levels of rivaroxaban, apixaban, and dabigatran. Moreover, carriers of the variant genotype of the SNP (rs776746) in the cytochrome P450 3A5 enzyme-encoding gene (CYP3A5) had significantly higher drug levels when compared with the non-carriers. In contrast, some SNPs were reported to impart a protective phenotype to the carrier. The SNP (rs2244613) in the carboxylesterase-encoding gene (CES1) has been significantly associated with a decline in dabigatran trough levels and a lower risk of hemorrhage. Further investigations are essential to elucidate the extent of pharmacogenetics-based alterations in the drug levels as well as the subsequent clinical outcomes of anticoagulant therapy." @default.
• W4312297198 created "2023-01-04" @default.
• W4312297198 creator A5007063400 @default.
• W4312297198 creator A5007258769 @default.
• W4312297198 creator A5059673337 @default.
• W4312297198 date "2022-01-01" @default.
• W4312297198 modified "2023-09-24" @default.
• W4312297198 title "A review of pharmacogenetics of anticoagulant therapy: Heparins, rivaroxaban, apixaban, and dabigatran" @default.
• W4312297198 cites W1966613914 @default.
• W4312297198 cites W2063280109 @default.
• W4312297198 cites W2066251905 @default.
• W4312297198 cites W2080318130 @default.
• W4312297198 cites W2122667952 @default.
• W4312297198 cites W2131231933 @default.
• W4312297198 cites W2312567072 @default.
• W4312297198 cites W2399437025 @default.
• W4312297198 cites W2467616965 @default.
• W4312297198 cites W2518583188 @default.
• W4312297198 cites W2559528249 @default.
• W4312297198 cites W2562806729 @default.
• W4312297198 cites W2621404381 @default.
• W4312297198 cites W2730172418 @default.
• W4312297198 cites W2733927229 @default.
• W4312297198 cites W2743553934 @default.
• W4312297198 cites W2802822232 @default.
• W4312297198 cites W2889256743 @default.
• W4312297198 cites W2896426515 @default.
• W4312297198 cites W2905636443 @default.
• W4312297198 cites W2909073103 @default.
• W4312297198 cites W2970271704 @default.
• W4312297198 cites W2975999253 @default.
• W4312297198 cites W2981083600 @default.
• W4312297198 cites W3026400664 @default.
• W4312297198 cites W3043483784 @default.
• W4312297198 cites W3048227011 @default.
• W4312297198 cites W3082833284 @default.
• W4312297198 cites W3108572624 @default.
• W4312297198 doi "https://doi.org/10.4103/mjbl.mjbl_71_22" @default.
• W4312297198 hasPublicationYear "2022" @default.
• W4312297198 type Work @default.
• W4312297198 citedByCount "0" @default.
• W4312297198 crossrefType "journal-article" @default.
• W4312297198 hasAuthorship W4312297198A5007063400 @default.
• W4312297198 hasAuthorship W4312297198A5007258769 @default.
• W4312297198 hasAuthorship W4312297198A5059673337 @default.
• W4312297198 hasConcept C104317684 @default.
• W4312297198 hasConcept C126322002 @default.
• W4312297198 hasConcept C135763542 @default.
• W4312297198 hasConcept C153209595 @default.
• W4312297198 hasConcept C2776301958 @default.
• W4312297198 hasConcept C2776318485 @default.
• W4312297198 hasConcept C2778205648 @default.
• W4312297198 hasConcept C2778661090 @default.
• W4312297198 hasConcept C2778810321 @default.
• W4312297198 hasConcept C2779161974 @default.
• W4312297198 hasConcept C2780638905 @default.
• W4312297198 hasConcept C3946865 @default.
• W4312297198 hasConcept C526171541 @default.
• W4312297198 hasConcept C54355233 @default.
• W4312297198 hasConcept C55775858 @default.
• W4312297198 hasConcept C62231903 @default.
• W4312297198 hasConcept C71924100 @default.
• W4312297198 hasConcept C86803240 @default.
• W4312297198 hasConcept C98274493 @default.
• W4312297198 hasConceptScore W4312297198C104317684 @default.
• W4312297198 hasConceptScore W4312297198C126322002 @default.
• W4312297198 hasConceptScore W4312297198C135763542 @default.
• W4312297198 hasConceptScore W4312297198C153209595 @default.
• W4312297198 hasConceptScore W4312297198C2776301958 @default.
• W4312297198 hasConceptScore W4312297198C2776318485 @default.
• W4312297198 hasConceptScore W4312297198C2778205648 @default.
• W4312297198 hasConceptScore W4312297198C2778661090 @default.
• W4312297198 hasConceptScore W4312297198C2778810321 @default.
• W4312297198 hasConceptScore W4312297198C2779161974 @default.
• W4312297198 hasConceptScore W4312297198C2780638905 @default.
• W4312297198 hasConceptScore W4312297198C3946865 @default.
• W4312297198 hasConceptScore W4312297198C526171541 @default.
• W4312297198 hasConceptScore W4312297198C54355233 @default.
• W4312297198 hasConceptScore W4312297198C55775858 @default.
• W4312297198 hasConceptScore W4312297198C62231903 @default.
• W4312297198 hasConceptScore W4312297198C71924100 @default.
• W4312297198 hasConceptScore W4312297198C86803240 @default.
• W4312297198 hasConceptScore W4312297198C98274493 @default.
• W4312297198 hasIssue "3" @default.
• W4312297198 hasLocation W43122971981 @default.
• W4312297198 hasLocation W43122971982 @default.
• W4312297198 hasOpenAccess W4312297198 @default.
• W4312297198 hasPrimaryLocation W43122971981 @default.
• W4312297198 hasRelatedWork W1980555552 @default.
• W4312297198 hasRelatedWork W1984967682 @default.
• W4312297198 hasRelatedWork W2065357039 @default.
• W4312297198 hasRelatedWork W2167924766 @default.
• W4312297198 hasRelatedWork W2387962570 @default.
• W4312297198 hasRelatedWork W2464186476 @default.
• W4312297198 hasRelatedWork W2530461753 @default.
• W4312297198 hasRelatedWork W2741829680 @default.
• W4312297198 hasRelatedWork W2908436399 @default.
• W4312297198 hasRelatedWork W3202697683 @default.

• next